Prevalence of Obesity and Its Impact on Outcome in Patients With COVID-19: A Systematic Review and Meta-Analysis

Basit Öğe Kaydı
dc.authoridYildiz, Bulent O. / 0000-0003-1797-7662
dc.authorwosidYildiz, Bulent O. / ABD-7781-2020
dc.contributor.authorHelvaci, Nafiye
dc.contributor.authorEyupoglu, Nesrin Damla
dc.contributor.authorKarabulut, Erdem
dc.contributor.authorYildiz, Bulent Okan
dc.date.accessioned2021-11-01T15:05:35Z
dc.date.available2021-11-01T15:05:35Z
dc.date.issued2021
dc.department[Belirlenecek]
dc.description.abstractBackground and Objective Obesity has been reported as a risk factor for adverse outcomes in COVID-19. However, available studies presenting data on obesity prevalence in patients with COVID-19 have conflicting results. The objective of this systematic review and meta-analysis is to evaluate the prevalence of obesity in these patients and to stratify the estimates by illness severity. Methods We performed a literature search with the use of Medline/PubMed and Google Scholar database from December 1, 2019 to June 27, 2020 and systematically reviewed studies reporting the number of obese patients with real-time reverse transcriptase polymerase chain reaction (rRT-PCR)-confirmed SARS-CoV-2 infection. Results Nineteen studies were identified. The pooled obesity prevalence rates were 0.32 (95% CI: 0.24-0.41) in hospitalized patients, 0.41 (95% CI: 0.36-0.45) in patients admitted to intensive care unit, 0.43 (95% CI: 0.36-0.51) in patients needing invasive mechanic ventilation (IMV), and 0.33 (95% CI: 0.26-0.41) in those who died. Obesity was associated with a higher risk for hospitalization [Odds ratio (OR): 1.3, 95% CI: 1.00-1.69; I-2 52%, p = 0.05], ICU admission (OR: 1.51, 95% CI: 1.16-1.97; I-2 72%, p = 0.002), and IMV requirement (OR: 1.77, 95% CI: 1.34-2.35; I-2 0%, p < 0.001). The increase in risk of death did not reach statistical significance (OR: 1.28, 95% CI: 0.76-2.16, p = 0.35) which might be due to obesity survival paradox and/or unidentified factors. Conclusions Our data indicate that obese subjects may be at higher risk for serious illness if infected and obesity may play a role in the progression of COVID-19.
dc.identifier.doi10.3389/fendo.2021.598249
dc.identifier.issn1664-2392
dc.identifier.pmid33716962
dc.identifier.scopus2-s2.0-85102373549
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.3389/fendo.2021.598249
dc.identifier.urihttps://hdl.handle.net/11491/7335
dc.identifier.volume12en_US
dc.identifier.wosWOS:000627361000001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthor[Belirlenecek]
dc.language.isoen
dc.publisherFrontiers Media Sa
dc.relation.ispartofFrontiers In Endocrinology
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectobesityen_US
dc.subjectbody mass indexen_US
dc.subjectCOVID-19en_US
dc.subjectSARS-CoV-2en_US
dc.subjectprognosisen_US
dc.titlePrevalence of Obesity and Its Impact on Outcome in Patients With COVID-19: A Systematic Review and Meta-Analysis
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu